Intellia narrows loss as HAE data clears path for FDA submission

Intellia Therapeutics (NASDAQ:NTLA) reported a narrowed net loss of $96.2 million for the first quarter of 2026, compared to $114.3 million in the prior-year period.

The financial improvement accompanied a series of de-risking clinical milestones, most notably the successful topline results from the Phase 3 HAELO trial of its lead candidate, lonvo-z.

The trial, which evaluates lonvo-z as a one-time treatment for hereditary angioedema (HAE), met its primary and all key secondary endpoints with high statistical significance (p<0.0001).

A single dose reduced monthly HAE attacks by 87% compared to placebo, with 62% of patients remaining entirely attack-free during the six-month evaluation period.

Based on these results, Intellia has initiated a rolling Biologics License Application (BLA) with the FDA and expects a potential U.S. commercial launch in the first half of 2027.

The company also resolved significant regulatory headwinds during the quarter as the FDA lifted clinical holds on the MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z.

The trials, which target transthyretin (ATTR) amyloidosis, were paused in late 2025 following a patient death.

After aligning on enhanced liver monitoring and safety protocols, Intellia has resumed patient screening and aims to complete enrollment for the polyneuropathy (MAGNITUDE-2) study by the end of 2026.

Intellia ended the quarter with $517.2 million in cash and marketable securities.

This was further bolstered by an April follow-on equity offering that raised approximately $207 million in gross proceeds.

Management stated that this capital provides a runway into 2028, covering the anticipated launch of lonvo-z and the continued advancement of its ATTR and hemophilia programs.

Meanwhile, collaboration revenue for the quarter was $15 million, slightly down from $16.6 million a year ago, while R&D expenses decreased to $80.7 million as the company optimized its clinical spending.